Company Overview of Icon Bioscience Inc.
Icon Bioscience Inc., a biopharma company, develops and commercializes ophthalmic pharmaceutical products. It offers its products for various ophthalmic indications, including glaucoma, macular edema, and inflammation/infection associated with cataract surgery and age-related macular degeneration. The company was incorporated in 2004 and is based in Sunnyvale, California.
1253 Reamwood Avenue
Sunnyvale, CA 94089
Founded in 2004
Key Executives for Icon Bioscience Inc.
Chief Executive Officer and President
Vice President of Clinical & Medical Affairs
Manufacturing & Operations Advisor
Vice President of Quality & Compliance
Compensation as of Fiscal Year 2015.
Icon Bioscience Inc. Key Developments
Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090
Apr 6 15
Icon Bioscience Inc. announced that Phase 3 data showed significantly positive outcomes for IBI-10090 compared to placebo in treating inflammation associated with cataract surgery. The Phase 3 study of IBI-10090, completed in the fourth quarter of 2014, was a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial involving 394 patients. The ensuing analysis of data shows IBI-10090 - with regard to both primary and secondary study endpoints - to be safe as well as highly effective. IBI-10090 utilizes the Verisome technology to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery. With over 3 million cataract surgeries in the US annually and with the standard of care for associated inflammation being a comparably burdensome, protracted process of multiple daily eye drops, IBI-10090 addresses a clear medical need in a large ophthalmic pharmaceutical space.
Icon Bioscience, Inc. Completes Treatment in its Pivotal Phase 3 Study of IBI-10090
Oct 6 14
Icon Bioscience, Inc. announced that the last patient has completed treatment in its pivotal Phase 3 study of IBI-10090. Top-line data is expected to be reported in the fourth quarter of 2014. Employing Icon's Verisome technology, IBI-10090 is designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery.
Icon Bioscience Announces Early Completion of Patient Enrollment in its Phase 3 Study of IBI-10090
Jun 30 14
Icon Bioscience, Inc. announced the completion of patient enrollment in its pivotal phase 3 study of IBI-10090, approximately four months ahead of projected timelines. IBI-10090, which employs the Verisome technology, is Icon's lead pipeline product. It has been designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery. With some three million cataract surgeries performed annually in the US alone, IBI-10090 addresses a potentially large market. Moreover, the current standard of care for inflammation associated with cataract surgery involves a comparatively burdensome process of patient administered eye drops applied topically several times daily over an extended time period.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 19, 2015